Healthy Athletes
Conditions
Keywords
luteolin, athlete, MEF-2, SREBP-1, anaerobic performance, body composition
Brief summary
A clinical trial is to determine whether Luteolin supplementation can enhance cellular metabolism and improve physical performance in apparently healthy Jordanian male athletes aged 18-35 with continuous training experience. The main questions it aims to answer are: * Does 12 weeks of Luteolin supplementation increase the gene expression of MEF2 (a factor promoting muscle development and endurance)? * Does 12 weeks of Luteolin supplementation decrease the gene expression of SREBP-1 (a factor regulating fat storage)? * Does Luteolin supplementation lead to improvements in key performance metrics, such as maximal oxygen consumption VO2 max) and anaerobic power? * Does Luteolin supplementation positively impact body composition, specifically by reducing fat mass and increasing lean muscle mass? Researchers will compare the group receiving the active Luteolin supplement (100 mg daily) to a placebo group receiving a microcrystalline cellulose supplement (a neutral substance) to determine whether the active supplement has the desired effects on metabolism, performance, and body composition. Participants will: * Take one capsule (either Luteolin or placebo) daily for 12 weeks. * Continue their usual diet and exercise regimen but restrict intake of high-Luteolin foods during the study period. * Provide a blood sample for gene expression analysis before and after the 12-week intervention. * Undergo performance assessments, VO2 max and Wingate test, and body composition analysis (BIA) before and after the 12-week intervention.
Detailed description
This study is designed to evaluate Luteolin's potential to optimize metabolic health and physical performance in athletes by modulating specific transcription factors. * Rationale: Effective management of lipid metabolism and enhanced muscle function are critical for athletic performance. Luteolin has shown in recent studies the potential to modulate gene expression, specifically activating MEF2 and downregulating SREBP-1. * MEF2 Focus: Activation of MEF2 is linked to enhanced oxidative capacity, promotion of mitochondrial biogenesis, and improved muscle endurance, which are highly beneficial for athletes. Luteolin is thought to enhance MEF2 activity by promoting histone deacetylation. * SREBP-1 Focus: SREBP-1 controls the expression of genes responsible for the synthesis of fatty acids and triglycerides. Downregulation of SREBP-1 is desirable for athletes to prevent excessive lipid accumulation and support better metabolic health and performance. Luteolin can inhibit the maturation of SREBP-1, reducing its activity and the expression of lipogenic genes. * Design: A multi-center, double-blinded, placebo-controlled clinical trial will be conducted, requiring a total sample size of 50 male athletes. Outcome assessments include Real-Time PCR on blood samples for gene expression , Wingate and Vmax tests for performance , and Bioelectrical Impedance Analysis (BIA) for body composition.
Interventions
DIETARY_SUPPLEMENTluteolin
100 mg Luteolin (Active Ingredient), taken orally once daily for 12 weeks.
OTHERPlacebo
Microcrystalline cellulose (Placebo), taken orally once daily for 12 weeks. The capsule is matched in size, color, and taste to the active Luteolin supplement.
Sponsors
University of Jordan
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Outcomes Assessor)
Masking description
Masking Description
Intervention model description
Model Description
Eligibility
Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Gender and Age: Male volunteers aged 18 to 35 years old. Athletic Status: Currently training male athletes with continuous sports training experience in any field (e.g., endurance, team sports, strength training). Health Status: Apparently healthy, with no known chronic diseases or metabolic disorders that could interfere with lipid or muscle metabolism (e.g., diabetes, liver disease, kidney disease, cardiovascular disease). Geographic Location: Must be residing in Jordan for the duration of the study and able to attend all scheduled assessment sessions at the specified study centers (University of Jordan). Informed Consent: Must provide voluntary written informed consent to participate in the study.
Exclusion criteria
* Pre-existing Conditions: Diagnosis of any chronic diseases, including cardiovascular disease, hypertension, diabetes mellitus, kidney disease, or any diagnosed neurological or immune system disorders. * Medication Use: Currently using any prescription medications that could influence lipid metabolism, inflammatory status, or exercise performance (e.g., corticosteroids, statins, certain anti-inflammatory drugs). * Supplement Use: Current or recent use (within the last 3 months) of any nutritional supplements Luteolin containing supplements. Failure to agree to restrict consumption of Luteolin-rich foods throughout the 12-week intervention period. * Study Commitment: Inability or unwillingness to comply with the study protocol, including the 12-week daily capsule intake and attendance at all assessment visits.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in SREBP-1 Gene Expression | Baseline (Week 0) and End of Intervention (Week 12) | Gene expression of SREBP-1 (Sterol Regulatory Element-Binding Protein 1) measured using Real-Time Polymerase Chain Reaction (RT-PCR) on collected salivary samples. The outcome is the fold change in expression from baseline to Week 12. |
| Change in MEF2 Gene Expression | Baseline (Week 0) and End of Intervention (Week 12) | Gene expression of MEF2 (Myocyte Enhancer Factor 2) measured using Real-Time Polymerase Chain Reaction (RT-PCR) on collected blood samples. The outcome is the fold change in expression from baseline to Week 12. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Maximal Oxygen Consumption (Vo2 max) | Baseline (Week 0) and End of Intervention (Week 12) | VO2 max will be assessed via an incremental exercise test (e.g., Bruce protocol or similar) to measure cardiorespiratory fitness. |
| Change in Anaerobic Power (Wingate Test) | Baseline (Week 0) and End of Intervention (Week 12) | Peak and average anaerobic power will be determined using the standard 30-second Wingate Anaerobic Power Test. |
| Change in Body Composition (Fat Mass and Lean Mass) | Baseline (Week 0) and End of Intervention (Week 12) | Percentage of body fat and total lean muscle mass will be assessed using Bioelectrical Impedance Analysis (BIA). |
Countries
Jordan
Outcome results
None listed